The findings strongly support that unecritinib should become one of the standards of care for NSCLC harboring ROS1 rearrangements, particularly those patients with baseline brain metastases or CD74-ROS1 fusions, and further clinical development of unecritinib for NSCLC with ALK rearrangement is warranted. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.